M&A Deals Analysis: Big Bucks Are Back
Executive Summary
September M&A deals picked up after a quiet summer with 23 M&A deals recorded, the busiest month of the year so far, which included two major deals closing at $4bn.
You may also be interested in...
Boston Scientific Buys EndoChoice, Mulls De-FUSEing Potential Weakness
Boston Scientific is making a significant investment in its endoscopy portfolio as it strikes a $210m deal to buy colonoscopy specialist EndoChoice. The Natick, Massachusetts, group added that it will be “evaluating strategic options” for EndoChoice’s Fuse colonoscope.
J&J Buys Abbott's Ophthalmics Business For $4bn-Plus
The move to sell Abbott Medical Optics unit comes in the midst of a significant portfolio overhaul by Abbott. The deal will put J&J in the ophthalmic surgery business.
Danaher Buys Cepheid For $4bn, Citing Molecular Diagnostics Strength
Danaher is paying a 54% premium to acquire Cepheid, maker of the fully automated GeneXpert rapid genetic testing system. Cepheid will join Danaher's $5bn Diagnostics segment, which already includes Beckman Coulter, Leica Biosystems and Radiometer. Danaher executives cited Cepheid's large installed base and potential for growth and efficiency improvements as justifications for the deal. At least one analyst believes Danaher may be paying too much.